MPO Inhibitors Selected by Virtual Screening.

Area of Science:

• Biochemistry
• Pharmacology
• Drug Discovery

Background:

• Myeloperoxidase (MPO) is crucial for innate immunity but also drives inflammation and tissue damage.
• Developing selective MPO inhibitors is therapeutically important for managing inflammatory conditions.

Purpose of the Study:

• To identify novel and selective myeloperoxidase (MPO) inhibitors using structure-based drug design (SBDD) and ligand-based drug design (LBDD).

Main Methods:

• Developed a pharmacophore model based on MPO-salicylhydroxamic acid complex.
• Screened the ZINC database and filtered compounds using physical-chemical properties and docking scores.
• Experimentally validated selected compounds for MPO inhibitory activity.

Main Results:

• Virtual screening identified aromatic hydrazides as potent MPO inhibitors.
• Selected compounds inhibited MPO chlorinating activity, with IC50 values from 1.0 to 2.8 µM.
• The most effective compound demonstrated irreversible MPO inactivation.

Conclusions:

• SBDD and LBDD are effective strategies for the rational design of new MPO inhibitors.
• Identified potent MPO inhibitors with potential therapeutic applications in inflammatory diseases.